SyStemix (US) tests stem cell sorter in myeloma patients:
This article was originally published in Clinica
SyStemix (US) says it has approval to commence US and European trials of its haematopoeitic stem cell (HSC) sorter in multiple myeloma patients. Dr Chris Reading, director of cell processing at SyStemix, says the sorter can isolate HSCs at speeds up to 30,000 cell a second and can produce 90%-pure cell populations, free of tumour cells from multiple myeloma patients' blood, in a single step.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.